CBU
BCRX icon

CIBC Bancorp USA’s BioCryst Pharmaceuticals BCRX Stock Holding History

CIBC Bancorp USA’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$129K Buy
12,883
+1,485
+13% +$13.4K ﹤0.01% 1833
2026
Q1 		$109K Buy
+11,398
New +$88.5K ﹤0.01% 1674
2025
Q3 		$169K Buy
+22,330
New +$186K ﹤0.01% 1301

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

CIBC Bancorp USA's BCRX Position: Q2 2026 in Review

CIBC Bancorp USA increased its BioCryst Pharmaceuticals (BCRX) stake by 13% in Q2 2026, buying an estimated $13.4K and bringing the position to 12,883 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #1833.

CIBC Bancorp USA first reported a position in BCRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $169K in Q3 2025. 296 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • CIBC Bancorp USA held 12,883 shares of BioCryst Pharmaceuticals worth $129K as of Q2 2026.
  • CIBC Bancorp USA bought 1,485 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $13.4K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1833 holding.
  • CIBC Bancorp USA first reported a position in BioCryst Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • CIBC Bancorp USA's BioCryst Pharmaceuticals position peaked at $169K in Q3 2025.
  • 296 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.